Table 2.
Assessment of the muscle power of the studied group of patients pre- and at the end of 6-month prednisone therapy
| DMD Range (Mean ± SD) | BMD Range (Mean ± SD) | LGMD Range (Mean ± SD) | ||||
|---|---|---|---|---|---|---|
| Muscle power assessment | Pre-treatment | Post-treatment | Pre-treatment | Post-treatment | Pre-treatment | Post-treatment |
| Muscle power assessment | ||||||
| Deltoid | 3–5 (3.8 ± 0.7) | 3–5 (4.3 ± 0.6)*** | 3–4a (3.9 ± 0.5) | 4b–5 (4.8 ± 0.3)** | 3–4b (3.5 ± 0.7) | 3–4a (3.4 ± 0.3) |
| Supraspinatus | 3–5 (3.8 ± 0.7) | 3–5 (4.3 ± 0.6)*** | 3–4a (3.8 ± 0.5) | 4b–5 (4.5 ± 0.2)** | 3–4b (3.4 ± 0.5) | 3–4b (3.5 ± 0.4) |
| Trapezius | 3–5 (3.8 ± 0.6) | 3–5 (4.3 ± 0.5)*** | 3–4a (3.8 ± 0.5) | 4a–5 (4.6 ± 0.3)** | 3–4b (3.5 ± 0.7) | 3–4a (3.6 ± 0.5) |
| Flexors of the shoulder | 2–5 (4.1 ± 0.8) | 2–5 (4.4 ± 0.7)*** | 4a–4b (4.7 ± 0.2) | 4b–5 (4.7 ± 0.3) | 3–4b (3.8 ± 0.6) | 3–4a (3.7 ± 0.7) |
| Extensors of the shoulder | 2–5 (4.0 ± 0.7) | 2–5 (4.3 ± 0.8)*** | 4a–4b (4.2 ± 0.3) | 4b–5 (4.6 ± 0.2)** | 3–4b (3.5 ± 0.7) | 3–4b (3.2 ± 1.0) |
| Adductors of the shoulder | 3–5 (3.9 ± 0.7) | 2–5 (4.4 ± 0.5)** | 4a–4b (4.1 ± 0.2) | 4b–5 (4.7 ± 0.3)*** | 3–4b (4.1 ± 0.5) | 2–4b (3.7 ± 0.7) |
| Biceps | 3–5 (4.3 ± 0.5) | 3–5 (4.5 ± 0.6)*** | 3–4b (4.0 ± 0.6) | 4b–5 (4.8 ± 0.3)** | 3–5 (4.1 ± 0.6) | 3–5 (4.1 ± 0.6) |
| Triceps | 3–5 (4.4 ± 0.5) | 3–5 (4.6 ± 0.5)** | 4a–4b (4.3 ± 0.3) | 4b–5 (4.8 ± 0.3)*** | 3–5 (4.3 ± 0.7) | 4a–5 (4.4 ± 0.5) |
| Iliopsoas | 1–4b (3.5 ± 0.8) | 1–4b (4.2 ± 0.8)*** | 1–4b (4.2 ± 0.8) | 4b–5 (4.8 ± 0.3) | 2–4b (3.5 ± 0.9) | 3–4b (3.5 ± 0.9) |
| Gluteus maximus | 1–4b (3.3 ± 0.8) | 1–4b (4.1 ± 0.9)*** | 3–4a (3.7 ± 0.5) | 4b (4.5 ± 0.0)* | 2–4a (2.6 ± 1.1) | 2–4b (2.9 ± 0.7) |
| Gluteus medius | 1–5 (3.7 ± 0.9) | 1–5 (4.1 ± 0.9)** | 3–4b (4.0 ± 0.6) | 4b–5 (4.8 ± 0.3) | 2–4b (3.3 ± 1.1) | 2–4b (3.1 ± 0.9) |
| Adductors of the thigh | 1–5 (3.6 ± 0.9) | 1–5 (4.1 ± 0.9)** | 3–4b (4.0 ± 0.6) | 4b–5 (4.8 ± 0.3) | 2–4b (3.2 ± 0.9) | 2–4b (3.1 ± 0.7) |
| Quadriceps | 1–5 (3.9 ± 0.8) | 1–5 (4.4 ± 0.7)** | 4a–4b (4.3 ± 0.3) | 4b–5 (4.8 ± 0.3)** | 3–5 (4.0 ± 0.6) | 4a–5 (3.8 ± 0.8) |
| Hamstring | 2–5 (3.9 ± 0.7) | 2–5 (4.4 ± 0.7)** | 4a–4b (4.3 ± 0.3) | 4b–5 (4.7 ± 0.3)** | 2–5 (3.5 ± 1.0) | 2–5 (3.6 ± 0.9) |
| Calves | 1–5 (4.2 ± 0.9) | 1–5 (4.5 ± 0.9)** | 4a–5 (4.7 ± 0.4) | 4b–5 (4.8 ± 0.3) | 4a–5 (4.7 ± 0.3) | 4a–5 (4.6 ± 0.5) |
| Tibialis anterior | 2–5 (4.3 ± 0.8) | 2–5 (4.6 ± 0.7)** | 4a–5 (4.7 ± 0.4) | 4b–5 (4.8 ± 0.3) | 4b–5 (4.7 ± 0.4) | 4b–5 (4.8 ± 0.3) |
BMD, Becker muscular dystrophies; DMD, Duchenne muscular dystrophies; LGMD, limb girdle muscular dystrophies.
*
P < 0.05
**
P < 0.01
***
P < 0.001.